LifeLiver
Seoul
About LifeLiver
LifeLiver rights to cell therapies HepaStem and H2Stem to treat liver diseases in South Korea. The companies will jointly develop the products to treat non-alcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF), and...
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Last round: Series Unknown (Jan 2011)
- Website: life-liver.co.kr
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/lifeliver-3385220 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.